The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter

被引：0
|
作者：
Leon, Leticia G. [1 ,2 ]
Funel, Niccola [1 ]
Peters, Godefridus J. [3 ]
Avan, Amir [4 ,5 ]
Vistoli, Fabio [6 ]
Boggi, Ugo [6 ]
Giovannetti, Elisa [1 ,3 ]
机构：
[1] Univ Pisa, Canc Pharmacol Lab, AIRC Start UP Unit, I-56124 Pisa, Italy
[2] Univ La Laguna, Ctr Biomed Res Canary Isl, Inst Tecnol Biomed, E-38207 San Cristobal la Laguna, Spain
[3] VU Univ Med Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands
[4] Mashhad Univ Med Sci, Dept Modern Sci & Technol, Sch Med, Mashhad, Iran
[5] Mashhad Univ Med Sci, Canc Res Ctr, Sch Med, Mashhad, Iran
[6] Univ Pisa, Div Gen & Transplant Surg, I-56124 Pisa, Italy
来源：
CLINICAL CANCER RESEARCH | 2016年 / 22卷 / 10期
关键词：
PANCREATIC-CANCER; ANTITUMOR-ACTIVITY;
D O I：
10.1158/1078-0432.CCR-16-0259
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2594 / 2594
页数：1
相关论文
共 50 条
  • [31] Putative allosteric MEK1 and MEK2 inhibitors
    Price, Steve
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (06) : 603 - 627
  • [32] Mek1 and Mek2 Functional Redundancy in Erythropoiesis
    Beuret, Laurent
    Fortier-Beaulieu, Simon-Pierre
    Rondeau, Vincent
    Roy, Sophie
    Houde, Nicolas
    Balabanian, Karl
    Espeli, Marion
    Charron, Jean
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [33] Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors
    Naing, A.
    Mita, M.
    Komarnitsky, P.
    Milner, A.
    von Richter, O.
    Ogden, J.
    Piha-Paul, S.
    Fu, S.
    Asatiani, E.
    Kurzrock, R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 187 - 187
  • [34] Selumetinib: a selective MEK1 inhibitor for solid tumor treatment
    Hedayat, Mohaddeseh
    Jafari, Reza
    Zolbanin, Naime Majidi
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (02) : 229 - 244
  • [35] Selumetinib: a selective MEK1 inhibitor for solid tumor treatment
    Mohaddeseh Hedayat
    Reza Jafari
    Naime Majidi Zolbanin
    Clinical and Experimental Medicine, 2023, 23 : 229 - 244
  • [36] Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors
    Monica Mita
    Siqing Fu
    Sarina Anne Piha-Paul
    Filip Janku
    Alain Mita
    Ronald Natale
    Wei Guo
    Charles Zhao
    Razelle Kurzrock
    Aung Naing
    Investigational New Drugs, 2017, 35 : 616 - 626
  • [37] MEK inhibition enhances gemcitabine efficacy by increasing MDM2-mediated ubiquitination and degradation of RRM1
    Vena, F.
    Li Causi, E.
    Hagemann, T.
    Hartley, J. A.
    Goodstal, S.
    Hochhauser, D.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 146 - 146
  • [38] ROLE OF THE COMBINATION MEK1/2 INHIBITOR BINIMETINIB AND AKT INHIBITOR MK2206 IN CLL
    Sandhu, S.
    Mulligan, S.
    Best, G.
    HAEMATOLOGICA, 2017, 102 : 409 - 410
  • [39] Antiviral Activity of the MEK1/2 Inhibitor Trametinib Against Lymphocytic Choriomeningitis Virus
    Mao, Wenting
    Wan, Yi
    Liu, Yang
    Zhou, Minmin
    Jia, Xiaoying
    Hou, Yuxia
    Wang, Wei
    JOURNAL OF MEDICAL VIROLOGY, 2025, 97 (03)
  • [40] Characterizing a Canine Urothelial Carcinoma Model of Acquired MEK1/2 Inhibitor Resistance
    Duval, Dawn L.
    Idate, Rupa
    Das, Sunetra
    Ackart, David
    Gustafson, Daniel L.
    Cronise, Kathryn
    FASEB JOURNAL, 2022, 36
12345